EcoDrugPlus

Plasminogen Activator, Tissue Type

Ensembl ID : ENSCVAG00000018691
Gene Symbol: PLAT
3 Cross references
207 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSCVAG00000010913
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSCVAG00000010932
Gene Symbol: PDGFRB
3 Cross references
199 Possible Orthologues:

Platelet-Activating Factor Acetylhydrolase-Like

Ensembl ID : ENSCVAG00000001540
Gene Symbol: LOC107097358
3 Cross references
206 Possible Orthologues:

Platelet-Activating Factor Receptor-Like

Ensembl ID : ENSCVAG00000011436
Gene Symbol: LOC107087569
2 Cross references
223 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSCVAG00000015714
Gene Symbol: LOC107102292
2 Cross references
174 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSCVAG00000018697
Gene Symbol: PLK1
4 Cross references
187 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSCVAG00000005606
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSCVAG00000021372
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSCVAG00000000616
Gene Symbol: PARP2
3 Cross references
186 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSCVAG00000001026
Gene Symbol: PARP3
3 Cross references
198 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSCVAG00000014058
Gene Symbol: PORCN
3 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).